Revolutionizing Cancer Diagnostics through Partnership
Collaboration integrates per-sample NGS internal standards with a multi-omic precision oncology platform to enhance cancer diagnostics accuracy and access.
Strategic Collaboration Announcement
AccuGenomics, Inc., a leader in next-generation sequencing (NGS) quality standards, has joined forces with 1Cell.Ai, a precision oncology company well-known for its expertise in single-cell and liquid biopsy diagnostics. This strategic partnership promises to deliver ultra-sensitive, actionable liquid biopsy testing across Asia. The focus is on significantly enhancing cancer patient care through advanced diagnostics by leveraging the capabilities of both companies.
Enhancing Liquid Biopsy Testing
Throughout their collaboration, 1Cell.Ai will adopt AccuGenomics' Accukit™ CRC/NSCLC Internal Standards, integrating these innovations into their OncoIndx panel, which is known for its ultra-sensitive NGS-based capabilities. This will provide vital quality control and sensitivity verification for every sample processed. The expected outcome is the rapid processing of tens of thousands of patient samples annually, facilitating better access to high-precision cancer testing in the region.
Internal Standards Impact
The Accukit™ CRC/NSCLC Internal Standards are groundbreaking synthetic controls designed for robust validation of assay performance. They are intended to detect clinically relevant mutations specifically in colorectal cancer (CRC) and non-small cell lung cancer (NSCLC). By implementing these standards, laboratories will improve analytical accuracy, reproducibility, and significantly lower the chances of false negatives, which are crucial in clinical settings.
Vision for Future Expansion
Nick Lazaridis, President of AccuGenomics, expressed enthusiasm about the partnership, stating, "We are thrilled to work with 1Cell.Ai to bring a new level of sensitivity and reliability to cancer diagnostics." This collaboration sets a new standard in oncology, with plans not only to improve cancer care currently available in Asia but also to expand into the U.S. market, offering advanced testing options.
Statements from Leadership
Mohan Uttarwar, CEO of 1Cell.Ai, stated, "This collaboration is pivotal for ensuring that each patient sample we analyze adheres to rigorous standards of accuracy." Through the integration of AccuGenomics' internal standards, 1Cell.Ai aims to deliver actionable insights, fulfilling their mission of making precision oncology testing both affordable and reliable across regions, and eventually in the United States.
About AccuGenomics
AccuGenomics, Inc., located in Wilmington, North Carolina, specializes in developing synthetic internal standards essential for next-generation sequencing (NGS). Their Accukit™ product line is recognized for offering per-sample quality control and ensuring LOD sensitivity assurance. AccuGenomics plays a critical role in enhancing the diagnostic accuracy and reproducibility necessary in clinical laboratories.
About 1Cell.Ai
1Cell.Ai, a precision oncology leader with bases in Mumbai, India, and a certified laboratory in Foster City, California, specializes in next-generation liquid biopsies. Their innovative Laboratory Developed Tests (LDTs) aim to improve cancer detection and biomarker discovery, renowned for providing insightful analysis that informs treatment decisions.
Frequently Asked Questions
What is the focus of the partnership between AccuGenomics and 1Cell.Ai?
The partnership is aimed at enhancing liquid biopsy testing to improve cancer diagnostics across Asia, with plans for future expansion into the U.S.
How is AccuGenomics contributing to this collaboration?
AccuGenomics provides its Accukit™ CRC/NSCLC Internal Standards to support quality control and sensitivity verification in cancer testing.
What benefits do the Accukit™ Internal Standards offer?
These standards validate assay performance and improve the accuracy and reliability of detecting mutations in colorectal and lung cancer samples.
What does 1Cell.Ai do?
1Cell.Ai specializes in precision oncology, particularly in single-cell and liquid biopsy diagnostics, aimed at improving cancer detection and patient care.
Where is AccuGenomics headquartered?
AccuGenomics is based in Wilmington, North Carolina, focusing on next-generation sequencing quality standards.
